In the Mix: 6 More Articles โ€” March 20, 2026

In the Mix: 6 More Articles โ€” March 20, 2026

In the Mix: 6 More Articles โ€” March 20, 2026
In the Mix โ€” Last 24 Hours
March 20, 2026. 6 articles reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score.
#25

Cannabis MSO Vireo Growth’s aggressive M&A is paying off

Vireo Growth, a cannabis multistate operator, achieved 250%+ revenue growth through acquisition strategy, demonstrating consolidation trends in the legal cannabis industry.

Read more →

#25

WNBA Offers To End Marijuana Testing For Women’s Basketball Players As Part Of …

Summary

The WNBA proposed eliminating marijuana testing for players during labor negotiations, representing a professional sports policy shift that may interest clinicians tracking cannabis normalization in workplace settings.

Read more →

#15

Willits man arrested after allegedly giving THC-laced popcorn to minors in Fort Bragg

A man was arrested for distributing THC-containing food to minors, illustrating real-world pediatric cannabis exposure risks and potential public health concerns relevant to clinical practice.

Read more →

#15

Knotts Island man arrested on drug charges – The Outer Banks Voice

Summary

Local arrest involving synthetic cannabinoids, with reference to NIDA’s definition of lab-synthesized compounds chemically similar to cannabis.

Read more →

#15

Marijuana companies suing Grand Rapids, others | wzzm13.com

Summary

Marijuana companies are suing Grand Rapids over missing funds from a city-mandated cannabis fund, raising questions about regulatory compliance and financial oversight in cannabis licensing frameworks.

Read more →

#15

Marijuana companies suing Grand Rapids, others – YouTube

Summary for Cannabis Clinician

This article reports on a lawsuit alleging $2 million missing from a Grand Rapids municipal marijuana fund, highlighting regulatory and compliance issues within cannabis business licensing frameworks.

Read more →


Digest-Level Clinical Commentary

Dr. Caplan’s Take
These digest items reflect three distinct pressures converging on cannabis medicine practice: the normalization of cannabis use across traditionally conservative institutions like professional sports, the persistent public health concern around unregulated product safety and accidental pediatric exposure, and ongoing regulatory-fiscal friction between cannabis businesses and municipalities that threatens the legitimacy of state-licensed markets. For clinicians, this suggests we need robust counseling frameworks on product sourcing and dosing verification, heightened vigilance regarding household storage safety in families with minors, and awareness that market instability and regulatory uncertainty may ultimately affect patient access to quality-assured products.
Clinical Perspective

These items reflect several concurrent developments in cannabis regulation and public health. The normalization of cannabis use is evident in policy shifts like the WNBA’s decision to end marijuana testing, while simultaneously, public health concerns persist regarding accidental pediatric exposure and synthetic cannabinoid misuse. Additionally, the cannabis industry’s rapid commercialization is generating both business consolidation through M&A activity and emerging disputes over regulatory compliance and financial accountability at the municipal level.

BusinessRegulationLaw EnforcementPolicy

💬 Join the Conversation

Have a question about how this applies to your situation?
Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers?
Join the forum discussion →

FAQ

This News item was assembled from structured source metadata and pipeline scoring.

Have thoughts on this? Share it: